Deutsch | English | по-русски | Türkçe 

Haemostaseology

Contact/Address

Herr PD Dr. Christian Langer

Department of Internal Medicine III

University Hospital of Ulm

Albert-Einstein-Allee 23

89081 Ulm

Germany

 

E-Mail: christian.langer[at]uniklinik-ulm.de

Phone:
Fax:

0049+(0)731-500-45732
0049+(0)731-500-45505

 

Project Leader

Herr PD Dr. Christian Langer

E-Mail: christian.langer[at]uniklinik-ulm.de

 

Scientific Lab Members

PD Dr. Christian Langer


Technicians

Anke Schmid

Carmen Engler-Royal

Ingrid Schoblocher

 

Students

Birgit Hetzl

Julia Klass

Research Fields

(A)
Essential Thrombocythemia (ET)

ET is a rare myeloproliferative disorder with an increased incidence of thromboembolic and hemorrhagic complications. In order to understand the pathophysiological mechanisms of hemostatic complications we investigate the role of the endogenous thrombin potential in ET in comparison with healthy controls (Project leader: C. Langer).

(B)

Pregnancy in patients with Ph-negative chronic myeloproliferative disorders
Within the WP 9.11 of the European Leukemia Net (ELN-Registry of pregnancies in CMPDs) we set up a registry of pregnancies in CMPDs. It is planed to offer clinicians facing such situations the opportunity to register these rare cases via a standardized questionnaire. We therefore developed such a questionnaire and a database to set up a European registry. For ethical and legal reasons a proposal is currently presented to the commission of ethical affairs of the University of Ulm (Project leader: ).

(C)
Vascular complications of conception and pregnancy
Efficacy and safety of prophylactic anticoagulation with low-molecular weight (LMW) heparin during pregnancies at an increased vascular risk is evaluated. In a prospective matched pair study, reasons for idiopathic implantation failure are investigated. Serial assessments of platelet activation, microparticle generation and thrombin generation are used. Elucidating the etiology of implantation failure may help to generate a therapeutic approach.

(D)
Congenital and acquired Hemophilia
Within the hemophilia center we take care of about 50 patients with severe hemophilia A and B. We take part in clinical trials evaluating the efficacy and safety of several factor VIII and factor IX concentrates (Project leader: M. Sparber-Sauer).
Acquired hemophilia is a rare, yet catastrophic event. The role of a combined factor replacement and immunosuppressive therapy has been evaluated. Currently, the role of Rituximab, a monoclonal CD 20 antibody, for the treatment of relapsed and refractory acquired hemophilia is investigated.

(E)

Idiopathic Thrombocytopenia (ITP)

ITP is an acquired autoimmune disease with a decreased platelet count and bleeding complications. We take part in clinical trials evaluating the efficacy and safety of novel treatment options (eg. AMG 531).

Techniques

    • Global coagulation tests:
      Thromboelastography, endogenous thrombin potential (ETP).
    • Differential coagulation tests:
      Numerous single factor determinations of pro- and anticoagulant and fibrinolytic factors.
    • Constitutional platelet tests:
      Flow cytometric assessment of Fibrinogen (CD 41, CD 61; PAC 1), von Willebrand Factor (CD 42b) and Collagen receptors (CD 29, CD 49b), and of a- and d-granular adhesion receptors (CD 62P, CD 63).
    • Functional platelet tests:
      Aggregation analyses, platelet-plug formation capacity (PFA 100), flow cytometric expression analyses after in vitro stimulation of the thrombin receptor.

      Grants/Funding

      • German Competence Network “Acute and Chronic Leukemias” (Research field A)
      • WP 9.11 of the European Leukemia Net (ELN-Registry of pregnancies in CMPDs)

      Representative Publications

      M Griesshammer: Risk factors and their influence on therapeutic decisions in patients with essential thrombocythemia.
      Semin Thromb Hemost 32: 372-380 (2006)

      M Griesshammer, S Struve, C Harrison: Essential thrombocythemia/Polycythemia vera and pregnancy: the need for a observational study in Europe.
      Semin Thromb Hemost 32: 422-429 (2006)
       

      Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdiles MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Briere J, Harrison CN, Green AR, Reilly JT. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
      Blood 107(5):2098-2100 (2006)
       

      Barosi G, Besses C, Birgegard G, J Briere, F Cervantes, G Finazzi, H Gisslinger, M Griesshammer, L Gugliotta, C Harrison, H Hasselbalch, E Lengfelder, JT Reilly, JJ Michiels, T Barbui.: A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
      Leukemia 21: 277-280 (2006)
       

      C Langer, E Lengfelder, J Thiele, HM Kvasnicka, H L Pahl, H Beneke, S Schauer, H Gisslinger, M Griesshammer: Pegylated Interferon for the treatment of high-risk essential thrombocythemia – Results of a phase II Study.
      Haematologica 90: 1333-1338 (2005)

      Collaborations

      Prof. Dr. M. Grießhammer
      Johannes Wessling Klinikum, Klink für Hämatologie und Onkologie, Minden

      Prof. Dr. H. Gisslinger
      Department of Internal Medicine I, University of Vienna, Allgemeines Krankenhaus

      Prof. Dr. A. Reiter, PD Dr. E. Lengfelder
      Department of Internal Medicine III, University of Heidelberg, Klinikum Mannheim

      Forschungsbereiche

      Molecular Genetics of Myeloid Leukemia
      Prof. Dr. Konstanze Döhner / Prof. Dr. Lars Bullinger

      Molecular Genetics of Myeloproliferative Disorders
      Dr. Frank Stegelmann / Prof. Dr. Konstanze Döhner

      Molecular Pathogenesis and Progression of Lymphoproliferative Disorders
      Prof. Dr. Stephan Stilgenbauer

      Mechanisms of Leukemogenesis
      PD Dr. Daniel Mertens

      Molecular Pathogenesis and Prognostic Markers in Monoclonal Gammopathies
      PD Dr. Christian Langer

      Tumor Immunology Group (TIG)
      Prof. Dr. Jochen Greiner

      Haemostaseology
      PD Dr. Christian Langer
       

      Molecular Hematopoiesis
      PD Dr. Dr. Florian Kuchenbauer

       

      Emmy Noether Research Group

      Dr. Jan Krönke

      gepunktete hellblaue Linie 176px breit
      gepunktete blaue Linie 1000px breit